Shanghai Vitalgen BioPharma Co., Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 1/2
GBA1/glucocerebrosidaseGene therapy / editing
Parkinson's Disease
Phase 1/2
AADC (aromatic L-amino acid decarboxylase)Gene therapy / editing
Parkinson's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
VGN-R08bPhase 1/2Parkinson Disease (PD)
Est. primary completion 2027-09-01 · NCT07414290 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
VGN-R08bPhase 1/2Gaucher Disease Type 3
Est. primary completion 2028-05-29 · NCT07603050 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.